Overview of Ol-citramons

Property	Description
Active ingredients	Acetaminophen, Acetylsalicylic acid, Caffeine
Form	Tablet
Pharmacological class	Analgesic, Antipyretic, NSAID
Common use	Relief of pain and fever syndrome
Origin	Synthetic, Small Molecule

What Type of Medicine is Ol-citramons?

Ol-citramons is an Over-The-Counter (OTC) combination preparation that functions primarily as an analgesic, antipyretic, and non-steroidal anti-inflammatory drug (NSAID). This formulation, often associated with the Citramon complex generic formula, is administered via the oral route as a solid tablet. The classification as an NSAID relates to the mechanism of action of the Acetylsalicylic acid component, which inhibits cyclooxygenase enzymes.

Why Does Ol-citramons Contain Three Ingredients?

The formulation contains three distinct Active ingredients—Acetaminophen, Acetylsalicylic acid, and Caffeine—designed to provide enhanced therapeutic efficacy through synergy. Acetaminophen and Acetylsalicylic acid address central and peripheral pain pathways, respectively. The strategic inclusion of Caffeine is recognized to enhance the analgesic effectiveness of the combination, increasing the speed and degree of relief compared to the components used alone. The combination of these three components is intended to provide benefits for acute pain conditions such as headache.

What is the General Purpose of This Combination Preparation?

The general purpose of the Ol-citramons combination preparation is the rapid, comprehensive management of generalized discomfort, including mild to moderate pain and the symptoms of fever syndrome. By utilizing this multi-component approach, the medicine simultaneously targets multiple pathways for pain perception and temperature regulation. The added stimulant component serves to potentiate the core relief and counteracts the symptoms of fatigue often associated with acute painful and febrile conditions, providing a distinct functional benefit.

What side effects are possible with Ol-citramons?

Possible Side Effects and Safety Information

The official safety profile for Ol-citramons, based on regulatory documentation, defines the known and potential risks associated with its active components: Acetylsalicylic Acid (Aspirin), Paracetamol (Acetaminophen), and Caffeine.

Adverse Reaction Categories

Adverse reactions are primarily documented across several System-Organ Classes (SOCs), reflecting the effects of the combination. Gastrointestinal disorders are a significant category due to Acetylsalicylic Acid, including the potential for irritation, ulcers, and bleeding. Hepatobiliary disorders (liver) are linked to the Paracetamol component, while Nervous System disorders (e.g., restlessness, insomnia, headache) are associated with Caffeine and Aspirin.

Serious Adverse Reactions and Safety Limitations

Serious adverse reactions highlighted in regulatory sources include acute liver failure (hepatotoxicity), which is often dose-dependent and necessitates prompt medical attention in cases of overdose. Significant gastrointestinal hemorrhage or ulceration represents another critical risk. The regulatory safety structure includes restrictions on the authorized patient population, limiting use to adults and children over 15 years of age. Furthermore, the risk of hepatotoxicity emphasizes a dose- or exposure-related pattern, with toxicity increasing with higher doses or exceeding the maximum recommended daily intake.

Contextual Safety Notes

Official documents mandate specific limitations on use, including contraindications for patients with active peptic ulcers, severe liver impairment, or late-stage pregnancy. The safety profile is defined by these mandated restrictions and serious warnings, which structure the understanding of the medicine's risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for an overdose of Ol-citramons is defined by the toxicological effects of its components: Acetaminophen, Acetylsalicylic acid, and Caffeine. The official guidance from government health authorities mandates that immediate medical attention must be sought for any suspected overdose, even if no initial symptoms are present.

Documented Manifestations and Severe Outcomes

Symptoms may initially include nausea, vomiting, diaphoresis, and malaise. Specific manifestations documented in regulatory labels include:

Salicylate Toxicity (ASA): Tinnitus, vertigo, hyperventilation leading to respiratory alkalosis, and later, severe metabolic acidosis.
Acetaminophen Toxicity: Potential for delayed, but life-threatening acute hepatic failure, which may progress to encephalopathy. Initial symptoms may be misleadingly mild or absent.
Caffeine Toxicity: Central nervous system excitation, restlessness, and tachycardia.

Official Emergency Actions

Contacting emergency services is required upon recognition of any severe toxicity, such as profound vomiting, confusion, or signs of cardiovascular collapse. Hospital monitoring is required for all suspected ingestions, as mandated by regulatory authorities, to assess hepatic function and acid-base status.

The specific antidote, N-acetylcysteine (NAC), is documented in official labeling as the required treatment for the acetaminophen component and must be administered promptly. Supportive and symptomatic care is also officially described for managing systemic complications.

Therapeutic Uses of Ol-citramons

The combination is used in situations involving certain distressing symptoms related to physical discomfort and systemic imbalance. The formulation is commonly used across conditions presenting with acute or episodic manifestations, and is considered relevant when short-term symptomatic assistance is needed. This combination is applied across various acute pain domains.

This combination helps address symptom clusters that may become intense or disruptive, including migraine attacks, recurrent tension-type headaches, toothaches, muscular aches, and discomfort associated with fever syndrome. It is generally applied in scenarios where additional management of discomfort is required.

“This approach is relevant across acute therapeutic contexts where symptoms create noticeable physiological strain.”

The formulation is relevant for easing symptoms related to systemic imbalance, like fever, and helps address symptom clusters that create noticeable functional strain, including the symptoms that accompany physical discomfort. This assists with maintaining functional stability when symptoms are more noticeable and contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relevant for Acute Discomfort and Fever

Regulatory References

Health Canada Guidance Document on Analgesics

Eligibility and Restrictions for Use

Who can and cannot use Ol-citramons?

The eligibility profile for Ol-citramons is determined by officially documented prohibitions and restrictions related to its three active components.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited for individuals with known hypersensitivity to Acetaminophen, Acetylsalicylic acid (ASA), Caffeine, or any other NSAID. Contraindications extend to patients with severe hepatic impairment or severe renal impairment, active peptic ulceration, gastrointestinal hemorrhage, severe uncontrolled heart failure, or significant bleeding disorders. Furthermore, due to the risk of Reye's syndrome associated with ASA, the medicine is contraindicated in children and adolescents recovering from viral illness. For pregnant women, use is contraindicated during the third trimester.

Populations for Whom Use is Restricted

The medicine is not recommended for general use in the pediatric population, while breastfeeding, or during the first and second trimesters of pregnancy. Use requires caution in older adults, as well as patients with mild to moderate hepatic or renal impairment, uncontrolled hypertension, or a history of gout. Regulatory documentation establishes that eligibility is strictly defined by these prohibitions and restrictions related to organ health, age, and reproductive status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify the interactions of Ol-citramons (Acetaminophen, Acetylsalicylic acid, Caffeine) based on pharmacokinetic and pharmacodynamic constraints.

Contraindicated Combinations and Restrictions

Co-administration with other Acetaminophen-containing products is strictly prohibited to avoid the documented risk of severe cumulative liver toxicity. Combining this medicine with Methotrexate doses exceeding 15 mg/ week is formally contraindicated, as the Acetylsalicylic acid (ASA) component causes a documented reduction in renal clearance of Methotrexate, leading to increased exposure and toxicity. In patients with a history of gastro-duodenal ulcers, co-administration with Oral Anticoagulants is prohibited due to the heightened risk of major haemorrhage.

Pharmacodynamic and Substance Interactions

The ASA component interacts with Oral Anticoagulants (e.g., Warfarin) and Selective Serotonin Reuptake Inhibitors (SSRIs), resulting in an officially classified additive risk of bleeding. Combining Ol-citramons with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) results in documented additive gastrointestinal toxicity. Use with Alcohol (Ethanol) is restricted due to the combined increase in the risk of both liver damage and stomach bleeding. Due to the Caffeine component, intake of other caffeine-containing products must be limited.

Procedural and Population Constraints

Official guidance requires the medicine to be discontinued several days prior to any scheduled surgery or dental procedures to mitigate the risk of bleeding complications. A population-specific caution is documented for elderly patients (aged 65 years and over) regarding an increased risk of haemorrhage when co-administered with Low Molecular Weight Heparins.

Mechanism of Action

Inhibition of Prostaglandin Synthesis

This mechanism targets and inhibits cyclooxygenase (COX) enzymes , which are essential for creating prostaglandins, the signaling molecules that sensitize nociceptors and regulate the hypothalamic set point. This action, primarily peripheral, modifies the initial molecular steps of nociceptor sensitization and modulates the hypothalamic set point, influencing heat loss mechanisms.

Central Nervous System (CNS) Pathway Modulation

The drug works centrally by acting as an antagonist of adenosine receptors and a modulator of central serotonergic pathways. By suppressing the neuromodulatory effects of adenosine, the medication promotes increased neural activity and alertness, while its serotonergic activity influences central pathways for signal processing.

Multi-Mechanistic Synergistic Action

The final physiological consequence arises from its engagement with multiple, distinct domains: both peripheral enzyme inhibition and central receptor modulation. This combination engages multiple mechanisms influencing peripheral signal generation and central signal processing, which results in a multi-system modification of physiological signaling.

Dosage and Administration Information

How to Use Ol-citramons

The administration of Ol-citramons, a combination analgesic and antipyretic preparation containing Acetaminophen, Acetylsalicylic acid (ASA), and Caffeine, follows standardized protocols.

Official Administration Protocol

The medicine is designed for oral administration, typically provided in the form of a tablet, caplet, or geltab. The standard adult single dose (for individuals 12 years of age and older) is 2 tablets, which delivers 500 mg of both Acetaminophen and ASA, plus 130 mg of Caffeine. This dose is taken with a full glass of water to facilitate ingestion.

Dosing Schedule and Regulatory Limits

Administration follows a structured as-needed frequency pattern, with a mandatory minimum interval of 6 hours between doses. Standardized Maximum Exposure Limits exist, prohibiting the use of more than 8 tablets in any 24-hour period. For children under the age of 12, use of this product is restricted and requires medical supervision.

Contextual Usage Constraints

The combination is intended exclusively for temporary relief of acute symptoms. Usage patterns are constrained, as the preparation is not intended for frequent or chronic consumption, with use limited to fewer than 10 days per month. Furthermore, administration protocols prohibit co-administration with any other product containing Acetaminophen and require users to limit the intake of other caffeine-containing substances to avoid exceeding established daily limits.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Neuropathic Pain (DPN and PHN)

Diabetic Peripheral Neuropathy (DPN) and Postherpetic Neuralgia (PHN)

This section outlines research that has explored the use of this drug in managing neuropathic pain, examining measures related to pain severity and emotional quality of life. Information on study findings regarding the drug’s effects is available for review.

Studies evaluated whether the drug was associated with changes in pain severity for participants with DPN and PHN. The primary measure used was the 11-point Pain Intensity Numeric Rating Scale (NRS). In some trials, a change in pain scores was observed during the initial four weeks of the study period.

Pain Relief: Research examined whether the drug was associated with changes in the emotional dimension of chronic pain and sleep quality in participants.
Quality of Life: Studies explored the effects on participants' self-reported mental health status and mood. Research also assessed whether the drug was associated with changes in self-reported anxiety.

Activity and Tolerability Profile

How Studies Suggested the Drug Might Act

Studies investigating the drug’s activity have focused on its central effects.

Pain Interference: Studies investigated whether the drug was associated with changes in both pain severity and pain interference.

Tolerability Considerations

The tolerability of the drug was assessed during the studies. The studies included observations concerning participants with pre-existing kidney function issues. Study protocols included examining different dosing schedules. The research evaluated the combination of treatments in study participants.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ol-citramons (FAQ)

Q: How long does the effect of one dose of Ol-citramons typically last?

Official dosing instructions specify a mandatory minimum interval of 6 hours between doses. This guidance establishes a safety limit that dictates the mandatory time required between doses, based on the pharmacokinetics and safety profile defined in regulatory documents.

Q: Why does the official guidance recommend a specific way of stopping Ol-citramons?

Regulatory guidance requires that the medicine be discontinued several days prior to scheduled surgery or dental procedures. This instruction is intended to help mitigate the documented risk of bleeding complications associated with the Acetylsalicylic acid (Aspirin) component.

Q: Are there any routine tests that may be needed while taking Ol-citramons?

Official product notes indicate that if this medication is used regularly for a long time or at high doses, certain lab and/or medical tests may be advised. These may include tests to monitor organ function, such as the liver and kidneys.

Q: Is Ol-citramons designed to treat symptoms or the underlying condition?

The medicine is officially authorized for the temporary relief of acute symptoms, such as minor aches and pains, and symptoms of fever. Its intended role is the temporary relief of symptoms, rather than addressing the underlying medical condition.

Q: Is Ol-citramons a type of pain reliever?

The product is officially classified as a pain reliever (analgesic), a pain reliever/fever reducer (antipyretic), and a pain reliever aid. This official classification indicates its intended use for the relief of general discomfort.

Q: Can Ol-citramons cause changes in sleep patterns?

Official safety information indicates that the Caffeine component can cause Central Nervous System (CNS) effects. This can result in sleeplessness (insomnia) or difficulty falling asleep, especially if the product is administered close to bedtime.

Q: Is it common to feel a little dizzy when first starting Ol-citramons?

The official side effect list includes dizziness and severe dizziness as potential adverse reactions. Patients who experience these effects are advised to report them as they may be related to the medication.

Q: Is Ol-citramons safe for use in older adults?

Regulatory documents mention an increased risk of stomach bleeding for individuals who are age 60 or older. This is due to the Acetylsalicylic acid (NSAID) component of the formulation.

Q: Is Ol-citramons chemically related to ibuprofen or acetaminophen?

Official labeling confirms that the product contains acetaminophen and aspirin (Acetylsalicylic acid). Aspirin is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), which is the same drug class as ibuprofen.

Q: Is it normal to have a slight headache when adjusting to Ol-citramons?

While headache is a listed side effect, regulatory labels caution that headaches may also worsen if the product is used too frequently. This is specifically noted if the medicine is taken for 10 or more days per month, and may lead to a condition known as medication overuse headache.

Q: Can Ol-citramons affect a person's ability to drive or operate machinery?

Adverse reactions to this medication, such as dizziness and other central nervous system (CNS) effects, are noted in the safety profile. These effects may impact performance of tasks that require high levels of concentration or alertness.

Q: Is there a risk of dependency or withdrawal associated with Ol-citramons?

Official warnings state that using the product for 10 or more days per month can result in medication overuse headache. This condition involves headaches worsening upon stopping the medicine, which is related to medication dependence.

Q: Can Ol-citramons affect blood pressure readings?

Regulatory labels advise that individuals with pre-existing conditions such as high blood pressure (hypertension) consult a doctor before using the product. This indicates that blood pressure is a factor that should be assessed before use.

Q: Does taking Ol-citramons for a long time change its effectiveness?

Regulatory documents warn that using the product for 10 or more days per month can potentially reverse the initial benefit. This overuse may lead to medication overuse headache, where the pain relief is diminished and headaches may worsen.

Q: What are the signs that Ol-citramons may not be working as intended?

Official product information advises patients to stop using the medication if their pain gets worse or lasts for more than 10 days. Similarly, if a fever gets worse or lasts for more than 3 days, consultation is advised.

Q: Are there any long-term safety concerns noted in regulatory documents for Ol-citramons?

Long-term use can increase the risk of serious adverse reactions, including severe stomach bleeding and liver damage. For extended periods of use, official sources suggest that lab tests may be required to monitor organ function.

Q: Can stress or illness change how Ol-citramons works?

Official labeling contains a specific safety warning regarding the Acetylsalicylic acid component. It should not be used in children and teenagers who have or are recovering from a viral illness (such as flu or chicken pox) due to the risk of Reye's syndrome.

Q: What should a patient know about the research evidence for Ol-citramons?

The medicine’s authorization is supported by studies that examined its use for the temporary relief of minor aches and pains and for some specific uses like migraine (depending on the product’s authorized label). This information is defined in official regulatory documents.

Q: Is there a link between Ol-citramons and mood changes?

Official safety documents list Central Nervous System (CNS) effects associated with the Caffeine component. These include nervousness and irritability, which are considered mood-related changes.

Q: What are the typical non-serious side effects that people experience?

Commonly reported non-serious effects, according to regulatory sources, may include nausea, vomiting, stomach upset, trouble falling asleep, or a shaky/nervous feeling. These are typically associated with the active ingredients in the product.

Q: Can people with a history of heart issues generally use Ol-citramons?

Regulatory warnings advise that individuals with a history of conditions such as heart disease or high blood pressure should consult a doctor before using the medication. This indicates that a medical assessment is an important step prior to use.

How should Ol-citramons be stored and disposed of?

How to Store and Dispose of Ol-citramons?

The storage and disposal of Ol-citramons (Acetaminophen, Acetylsalicylic acid, and Caffeine tablets) must strictly follow official regulatory guidelines to maintain product stability and ensure safety.

Storage Requirements

Temperature and Container: Store tablets at Controlled Room Temperature (20 C to 25 C). Keep the product in the original container with the cap tightly closed to protect it from moisture and excessive heat.
Prohibited Environments: Do not store the medicine in high-humidity areas, such as a bathroom, and do not freeze the tablets.
Child Safety: It is a mandatory requirement to keep the product out of the reach and sight of children to prevent accidental ingestion.

Disposal Instructions

Unused or Expired Product: The preferred method of disposal is to return the medicine to an authorized drug take-back program.
Household Disposal: If a take-back program is unavailable, mix the tablets with an unappealing substance (like dirt), seal the mixture in a plastic bag, and place it in the household trash. Do not flush the medicine down the toilet.

Ol-citramons